Berlin, 18 December 2017 – Medios AG (‘Medios’), one of the leading Specialty Pharma companies in Germany, has developed a new analytical method that can identify counterfeit solid drugs more quickly, safely and favourably than traditional methods.
The new analytical method is based on state-of-the-art FT-NIR spectroscopy (Fourier Transform Near-Infrared) that enables the user to identify the content of a solid drug by thermal radiation. As a result, the packaging does not have to be opened and the active ingredient remains sterile. Thus, the solid drug can continue to be used to produce infusion solutions. The thermal radiation measurement results are checked against the data files of a special reference library that Medios has built for this very purpose to see whether the analysed solid drug is an original or counterfeit. The entire process from the thermal radiation to the end result takes just one minute and has already been tested successfully by Medios. The new method is expected to be introduced in the Medios laboratories in early 2018 and could be offered to wholesalers and re-importers in the future.
Manfred Schneider, CEO of Medios AG: ‘Our innovative analytical method of identifying counterfeit solid drugs is far superior to the traditional methods because it cuts time and costs without affecting the reliability of the quality check. Thus, we create not only a competitive advantage for us but also make a significant contribution to the improvement of drug safety.’
With traditional analytical methods such as chromatography and mass spectroscopy, it can take around one week to identify the solid drug and determine whether it is an original or counterfeit. One reason for the higher temporal expenditure is that these analytical methods require physical samples. The associated opening of the packaging destroys the sterility of the ingredients and makes them unusable, which means that the samples must be destroyed according to the legislator.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Kirchhoff Consult AG
Telephone: +49 40 60918618
Fax: +49 40 60918660
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.